Recently, the first attempt in the United States to use the gene editing tool CRISPR to combat cancer appears to have gone well, according to the initial results of a small human trial to determine safety for the approach. Gene editing is a way to permanently change DNA in order to potentially cure a disease…

A human trial of NMN has recently concluded, and the results are not impressive at all; however, this is perfectly fine because that was not the purpose of the study, and, despite the lackluster results, the study was a success! This might sound strange, but perhaps the words of the study authors may make it…

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology. Dr. Greg Fahy of Intervene Immune gave a presentation about his company’s Phase 1 human trials in which the thymus,…

Recently, Unity Biotechnology completed a phase 1 trial of its drug UBX0101. While the trial found that the drug was non-toxic and lacked serious side effects, many of its results were not statistically significant. UBX0101 UBX0101 aims to treat osteoarthritis and possibly other diseases of aging through directly targeting one of the aspects of aging…

For the June edition of Journal Club, Dr. Oliver Medvedik and guests will be taking a look at the recent human trial of Urolithin A, a metabolite produced by microflora and an active ingredient in pomegranates which is linked to increased levels of mitophagy in aged animals. Join us at 13:00 EDT on our Facebook channel where…

A research team led by Professor Johann de Bono at the Institute of Cancer Research, London has successfully tested a new drug that has infiltrated different forms of cancer in an ongoing human trial [1]. The drug is called tisotumab vedotin (TV) and works like a ‘Trojan Horse’ by hiding a cancer-killing payload inside an…

Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies. SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised…

July is here, and our upcoming conference in New York City is only a handful of days away! If you haven’t done so already, go and get your ticket now so that you can enjoy the June roundup fully relaxed, knowing that your seat is secured. About our NYC conference On the off chance you’ve…

Earlier this month, there was a human clinical trial of the supplement MitoQ, which showed some interesting results. We thought that we would take a look at the data, and discuss the findings. Literature [1] Rossman, M. J., Santos-Parker, J. R., Steward, C. A., Bispham, N. Z., Cuevas, L. M., Rosenberg, H. L., … &…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD